Abstract:The pool of microbes inhabiting our body is known as "microbiota" and their collective genomes as "microbiome". The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition (dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases (inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract (e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies.

The Gut Core Microbial Species Bifidobacterium Longum: Colonization, Mechanisms, and Health Benefits

The Effect of Intrinsic Factors and Mechanisms in Shaping Human Gut Microbiota

Bifidobacterium spp. as functional foods: A review of current status, challenges, and strategies

Mining Lactobacillus and Bifidobacterium for Organisms with Long-Term Gut Colonization Potential.

The Human Microbiota in Health and Disease

Gut Colonization Mechanisms of <i>Lactobacillus</i> and <i>Bifidobacterium</i>: An Argument for Personalized Designs

Cross-feeding of bifidobacteria promotes intestinal homeostasis: a lifelong perspective on the host health

Modulation of Gut Microbiota in Pathological States

Bifidobacterium Longum: Protection against Inflammatory Bowel Disease

Mining <i>Lactobacillus</i> and <i>Bifidobacterium</i> for organisms with long-term gut colonization potential

Effects of Diet on Gut Microbiota Profile and the Implications for Health and Disease

Gut Bacteroides species in health and disease

Microbial interactions and the homeostasis of the gut microbiome: the role of Bifidobacterium

Gut Bifidobacteria Populations in Human Health and Aging

Bifidobacterium Breve Protects the Intestinal Epithelium and Mitigates Inflammation in Colitis Via Regulating the Gut Microbiota-Cholic Acid Pathway

Targeting gut microbiota and metabolism as the major probiotic mechanism-An evidence-based review

Bifidobacterium mechanisms of immune modulation and tolerance

Good or bad: gut bacteria in human health and diseases

Targeting the gut microbiota by dietary nutrients: A new avenue for human health

Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis

Bifidobacterium longum suppresses colorectal cancer through the modulation of intestinal microbes and immune function